Lantern Total Stockholder Equity vs Other Current Liab Analysis

LTRN Stock

USD 5.01 0.18 3.73%

Lantern Pharma financial indicator trend analysis is infinitely more than just investigating Lantern Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lantern Pharma is a good investment. Please check the relationship between Lantern Pharma Total Stockholder Equity and its Other Current Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

Total Stockholder Equity vs Other Current Liab

Total Stockholder Equity vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lantern Pharma Total Stockholder Equity account and Other Current Liab. At this time, the significance of the direction appears to have strong relationship.

The correlation between Lantern Pharma's Total Stockholder Equity and Other Current Liab is 0.72. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Lantern Pharma, assuming nothing else is changed. The correlation between historical values of Lantern Pharma's Total Stockholder Equity and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Lantern Pharma are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Total Stockholder Equity i.e., Lantern Pharma's Total Stockholder Equity and Other Current Liab go up and down completely randomly.

Correlation Coefficient

0.72

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Other Current Liab

Most indicators from Lantern Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lantern Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.As of the 18th of February 2025, Selling General Administrative is likely to drop to about 4.2 M. In addition to that, Enterprise Value Over EBITDA is likely to drop to -1.48

Lantern Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Other Assets	Other Current Assets
Total Assets		0.73	0.91	1.0	0.98	0.79	-0.97	-0.82	0.65	0.98	0.79	-0.01	1.0	-0.9	0.93	0.93	0.96	0.92	1.0	1.0	-0.89	1.0	-0.9	0.84	0.29	0.84
Other Current Liab	0.73		0.87	0.72	0.78	0.96	-0.57	-0.94	0.95	0.63	0.45	-0.16	0.73	-0.72	0.88	0.91	0.83	0.87	0.72	0.73	-0.72	0.73	-0.72	0.47	-0.18	0.82
Total Current Liabilities	0.91	0.87		0.91	0.95	0.84	-0.79	-0.92	0.77	0.83	0.58	-0.13	0.91	-0.81	0.99	0.93	0.98	1.0	0.91	0.92	-0.81	0.91	-0.81	0.62	0.01	0.93
Total Stockholder Equity	1.0	0.72	0.91		0.98	0.79	-0.97	-0.82	0.64	0.99	0.8	0.0	1.0	-0.9	0.93	0.93	0.96	0.91	1.0	1.0	-0.89	1.0	-0.9	0.85	0.3	0.83
Net Tangible Assets	0.98	0.78	0.95	0.98		0.83	-0.92	-0.87	0.71	0.94	0.75	-0.01	0.98	-0.9	0.97	0.94	0.99	0.96	0.98	0.98	-0.89	0.98	-0.9	0.79	0.21	0.87
Property Plant And Equipment Net	0.79	0.96	0.84	0.79	0.83		-0.66	-0.93	0.95	0.72	0.63	-0.05	0.79	-0.81	0.89	0.94	0.86	0.85	0.79	0.79	-0.8	0.79	-0.81	0.62	-0.01	0.76
Net Debt	-0.97	-0.57	-0.79	-0.97	-0.92	-0.66		0.69	-0.49	-1.0	-0.82	-0.04	-0.97	0.87	-0.81	-0.84	-0.88	-0.8	-0.97	-0.97	0.86	-0.97	0.87	-0.88	-0.42	-0.73
Retained Earnings	-0.82	-0.94	-0.92	-0.82	-0.87	-0.93	0.69		-0.94	-0.73	-0.47	0.0	-0.82	0.87	-0.92	-0.96	-0.92	-0.92	-0.82	-0.83	0.85	-0.82	0.87	-0.49	0.21	-0.92
Accounts Payable	0.65	0.95	0.77	0.64	0.71	0.95	-0.49	-0.94		0.55	0.39	0.05	0.65	-0.75	0.8	0.87	0.78	0.78	0.64	0.65	-0.73	0.65	-0.76	0.37	-0.3	0.77
Cash	0.98	0.63	0.83	0.99	0.94	0.72	-1.0	-0.73	0.55		0.83	0.03	0.98	-0.9	0.85	0.88	0.9	0.83	0.99	0.98	-0.88	0.98	-0.89	0.88	0.38	0.76
Non Current Assets Total	0.79	0.45	0.58	0.8	0.75	0.63	-0.82	-0.47	0.39	0.83		0.1	0.8	-0.62	0.65	0.66	0.68	0.59	0.8	0.79	-0.58	0.79	-0.62	0.98	0.74	0.36
Non Currrent Assets Other	-0.01	-0.16	-0.13	0.0	-0.01	-0.05	-0.04	0.0	0.05	0.03	0.1		-0.01	-0.12	-0.08	-0.01	0.0	-0.12	0.0	-0.01	0.04	0.0	-0.12	-0.03	-0.06	-0.01
Cash And Short Term Investments	1.0	0.73	0.91	1.0	0.98	0.79	-0.97	-0.82	0.65	0.98	0.8	-0.01		-0.9	0.93	0.93	0.96	0.92	1.0	1.0	-0.89	1.0	-0.9	0.84	0.3	0.84
Common Stock Total Equity	-0.9	-0.72	-0.81	-0.9	-0.9	-0.81	0.87	0.87	-0.75	-0.9	-0.62	-0.12	-0.9		-0.83	-0.92	-0.91	-0.83	-0.9	-0.9	0.99	-0.9	1.0	-0.65	-0.01	-0.85
Common Stock Shares Outstanding	0.93	0.88	0.99	0.93	0.97	0.89	-0.81	-0.92	0.8	0.85	0.65	-0.08	0.93	-0.83		0.95	0.98	0.99	0.93	0.93	-0.83	0.93	-0.83	0.68	0.07	0.91
Capital Surpluse	0.93	0.91	0.93	0.93	0.94	0.94	-0.84	-0.96	0.87	0.88	0.66	-0.01	0.93	-0.92	0.95		0.96	0.93	0.93	0.93	-0.91	0.93	-0.92	0.69	0.02	0.9
Other Stockholder Equity	0.96	0.83	0.98	0.96	0.99	0.86	-0.88	-0.92	0.78	0.9	0.68	0.0	0.96	-0.91	0.98	0.96		0.98	0.96	0.97	-0.89	0.96	-0.91	0.71	0.09	0.92
Total Liab	0.92	0.87	1.0	0.91	0.96	0.85	-0.8	-0.92	0.78	0.83	0.59	-0.12	0.92	-0.83	0.99	0.93	0.98		0.91	0.92	-0.83	0.92	-0.83	0.63	0.01	0.93
Net Invested Capital	1.0	0.72	0.91	1.0	0.98	0.79	-0.97	-0.82	0.64	0.99	0.8	0.0	1.0	-0.9	0.93	0.93	0.96	0.91		1.0	-0.89	1.0	-0.9	0.85	0.3	0.83
Total Current Assets	1.0	0.73	0.92	1.0	0.98	0.79	-0.97	-0.83	0.65	0.98	0.79	-0.01	1.0	-0.9	0.93	0.93	0.97	0.92	1.0		-0.89	1.0	-0.9	0.84	0.28	0.85
Capital Stock	-0.89	-0.72	-0.81	-0.89	-0.89	-0.8	0.86	0.85	-0.73	-0.88	-0.58	0.04	-0.89	0.99	-0.83	-0.91	-0.89	-0.83	-0.89	-0.89		-0.89	0.99	-0.64	-0.01	-0.84
Net Working Capital	1.0	0.73	0.91	1.0	0.98	0.79	-0.97	-0.82	0.65	0.98	0.79	0.0	1.0	-0.9	0.93	0.93	0.96	0.92	1.0	1.0	-0.89		-0.9	0.84	0.29	0.84
Common Stock	-0.9	-0.72	-0.81	-0.9	-0.9	-0.81	0.87	0.87	-0.76	-0.89	-0.62	-0.12	-0.9	1.0	-0.83	-0.92	-0.91	-0.83	-0.9	-0.9	0.99	-0.9		-0.65	-0.01	-0.85
Property Plant Equipment	0.84	0.47	0.62	0.85	0.79	0.62	-0.88	-0.49	0.37	0.88	0.98	-0.03	0.84	-0.65	0.68	0.69	0.71	0.63	0.85	0.84	-0.64	0.84	-0.65		0.74	0.42
Other Assets	0.29	-0.18	0.01	0.3	0.21	-0.01	-0.42	0.21	-0.3	0.38	0.74	-0.06	0.3	-0.01	0.07	0.02	0.09	0.01	0.3	0.28	-0.01	0.29	-0.01	0.74		-0.26
Other Current Assets	0.84	0.82	0.93	0.83	0.87	0.76	-0.73	-0.92	0.77	0.76	0.36	-0.01	0.84	-0.85	0.91	0.9	0.92	0.93	0.83	0.85	-0.84	0.84	-0.85	0.42	-0.26

Click cells to compare fundamentals

Lantern Pharma Account Relationship Matchups

Lantern Pharma fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	20.4M	74.0M	58.8M	43.6M	50.2M	36.4M
Other Current Liab	120K	1.5M	1.8M	2.5M	2.9M	3.0M
Total Current Liabilities	552.3K	2.3M	2.8M	2.7M	3.1M	1.7M
Total Stockholder Equity	19.7M	71.6M	56.0M	40.9M	47.0M	34.6M
Net Tangible Assets	943.0K	19.7M	71.6M	56.0M	64.4M	32.6M
Property Plant And Equipment Net	21.5K	216.2K	95.7K	280.4K	322.5K	338.6K
Net Debt	(19.1M)	(51.3M)	(37.1M)	(21.7M)	(19.5M)	(20.5M)
Retained Earnings	(12.7M)	(25.0M)	(39.3M)	(55.2M)	(49.7M)	(47.2M)
Accounts Payable	432.3K	681.1K	932.4K	2.5M	2.9M	3.0M
Cash	19.2M	51.5M	37.2M	21.9M	25.2M	24.1M
Non Current Assets Total	122.7K	1.2M	113.6K	306.3K	352.2K	363.2K
Non Currrent Assets Other	191K	101.2K	17.9K	25.9K	23.3K	22.1K
Cash And Short Term Investments	19.2M	70.7M	55.2M	41.3M	47.5M	34.5M
Common Stock Shares Outstanding	6.2M	10.9M	10.9M	10.8M	12.5M	9.4M
Liabilities And Stockholders Equity	20.4M	74.0M	58.8M	43.6M	50.2M	36.4M
Other Stockholder Equity	32.4M	96.7M	95.7M	96.3M	110.7M	61.0M
Total Liab	660.8K	2.4M	2.8M	2.7M	3.2M	1.8M
Net Invested Capital	19.8M	71.6M	56.0M	40.9M	47.0M	34.7M
Total Current Assets	20.2M	72.7M	58.7M	43.3M	49.8M	36.1M
Capital Stock	622.0	1.1K	1.1K	1.1K	964.8	916.56
Net Working Capital	19.7M	70.4M	55.9M	40.7M	46.8M	34.3M
Common Stock	622.0	1.1K	1.1K	1.1K	964.8	916.56
Property Plant Equipment	8.8K	21.5K	216.2K	48.0K	55.2K	65.8K
Other Current Assets	806K	1.0M	3.5M	2.5M	2.8M	1.7M
Property Plant And Equipment Gross	21.5K	216.2K	95.7K	280.4K	322.5K	338.6K

When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:

How To Invest In Lantern

Details

Is Lantern Stock a good investment?

Details

What is Lantern Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.78)

Return On Assets

(0.34)

Return On Equity

(0.53)

The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lantern Total Stockholder Equity vs Other Current Liab Analysis

Total Stockholder Equity vs Other Current Liab

Total Stockholder Equity vs Other Current Liab Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Other Current Liab

Lantern Pharma fundamental ratios Correlations

Lantern Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lantern Pharma fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities

Cash	- 1.0	Net Debt
Net Working Capital	- 0.97	Net Debt
Total Current Assets	- 0.97	Net Debt
Net Invested Capital	- 0.97	Net Debt
Cash And Short Term Investments	- 0.97	Net Debt
Net Debt	- 0.97	Total Stockholder Equity